Cyclin C is a haploinsufficient tumour suppressor

Area of Science:

• Molecular Biology
• Oncology
• Cell Cycle Regulation

Background:

• Cyclin C was initially identified as a G1 cyclin promoting cell growth and regulating gene transcription.
• Its role in tumor suppression and specific molecular mechanisms remained less understood.

Purpose of the Study:

• To investigate the in vivo function of cyclin C as a tumor suppressor.
• To elucidate the molecular mechanism by which cyclin C controls oncogene levels, specifically focusing on Notch1.

Main Methods:

• Utilized cyclin-C-knockout mice to study in vivo effects.
• Investigated the interaction of cyclin C with cyclin-dependent kinases (CDKs) CDK19, CDK8, and CDK3.
• Examined the phosphorylation and degradation of the Notch1 intracellular domain (ICN1).
• Analyzed human T-cell acute lymphoblastic leukemia (T-ALL) samples for CCNC gene deletions and mutations.

Main Results:

• In vivo, cyclin C acts as a haploinsufficient tumor suppressor by controlling Notch1 oncogene levels.
• Cyclin C forms complexes with CDK19, CDK8, and CDK3, which phosphorylate and promote the degradation of ICN1.
• Genetic ablation of cyclin C leads to elevated ICN1 levels in mice.
• Cyclin C deficiency accelerates T-ALL development when combined with other oncogenic factors.
• Human T-ALLs frequently exhibit heterozygous deletions of the CCNC gene, correlating with reduced cyclin C levels.
• Identified point mutations in human T-ALL that impair cyclin C-CDK complex function in phosphorylating ICN1.

Conclusions:

• Cyclin C is a critical regulator of Notch1 oncogene stability and functions as a haploinsufficient tumor suppressor.
• Dysregulation of cyclin C, through deletion or mutation, contributes to T-ALL pathogenesis.
• Tumor cells employ various strategies to evade cyclin C-mediated inhibition, highlighting its importance in cancer suppression.